Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols
A Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Napabucasin Protocols
Sponsor: Sumitomo Pharma America, Inc.
A PHASE1 clinical study on Oncology, this trial is completed. The trial is conducted by Sumitomo Pharma America, Inc. and has accumulated 12 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Dec 2023 — Jul 2024 [monthly]
Completed PHASE1
-
Nov 2023 — Dec 2023 [monthly]
Completed PHASE1
▶ Show 7 earlier versions
-
May 2022 — Nov 2023 [monthly]
Completed PHASE1
-
Dec 2021 — May 2022 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
May 2021 — Dec 2021 [monthly]
Active Not Recruiting PHASE1
Status: Enrolling By Invitation → Active Not Recruiting
-
Jan 2021 — May 2021 [monthly]
Enrolling By Invitation PHASE1
-
Nov 2020 — Jan 2021 [monthly]
Enrolling By Invitation PHASE1
-
Aug 2020 — Nov 2020 [monthly]
Enrolling By Invitation PHASE1
-
Apr 2020 — Aug 2020 [monthly]
Enrolling By Invitation PHASE1
First recorded
Feb 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sumitomo Pharma America, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .